Ben Izar's lab is a pioneer in combining single cell techniques, genome-editing, and systems biology to explore the cancer field’s most pressing problems.
Including BRCA1 testing with prenatal carrier screening could identify people at risk of breast, ovarian, and pancreatic cancer at a time when cancer screening could save their lives.
A study from Columbia researchers suggests that changing a single letter in the DNA code of selected genes in T cells may supercharge cell therapies against cancer.
Based on an analysis of withdrawn drugs that gained approval through the FDA's fast-track program, Columbia researchers argue that such programs have positively contributed to drug development.
A team of Columbia scientists is examining patient samples and experimenting with organoids to understand why colon cancer is on the rise in people under 50.
From Staten Island to Northern Manhattan, Columbia's Cancer Center works side by side with the communities it serves, putting research into action through programs that address critical needs.
In tests with mice, inhalable exosomes created by Columbia biomedical engineers successfully delivered cancer treatment to the lungs and suppressed tumor growth without toxic side effects.
Some cancer cells escape their tumors and stay dormant in other parts of the body before seeding metastases. Columbia researchers have identified a switch that could put the cells back to sleep.
A combination of a diabetes drug and a PI3K inhibitor may have potential in preventing melanoma from spreading to the liver, according to a study from Columbia cancer researchers.
A study from Columbia cancer researchers suggests drugs targeting the SMARCAL1 protein could strike a double blow against many cancers and make immunotherapy even more effective.